<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892398</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002ACA04T</org_study_id>
    <nct_id>NCT00892398</nct_id>
  </id_info>
  <brief_title>Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab</brief_title>
  <official_title>Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trabeculectomy with mitomycin C remains the standard surgery for glaucoma. This surgery&#xD;
      involves creating a door in the eye wall in order to improve fluid outflow and decrease&#xD;
      intraocular pressure. However, success rates range from 70% to 90% depending on the criteria&#xD;
      used and tend to decrease with time. The failure of the surgery is associated with&#xD;
      inflammation, new blood vessel formation and scarring which can cause closure of the door.&#xD;
      Molecules which inhibit new blood vessel formation such as inhibitors of vascular endothelial&#xD;
      growth factor have been used successfully to decrease scarring in animal eyes where little&#xD;
      doors were created and significantly improve survival. Furthermore, they have shown promise&#xD;
      when used during trabeculectomy. Ranibizumab, a vascular endothelial growth factor, has also&#xD;
      been used safely in intraocular surgery to treat other diseases which involve new blood&#xD;
      vessel formation such as macular degeneration and diabetes.&#xD;
&#xD;
      The investigators hypothesize that ranibizumab may decrease the failure rate of&#xD;
      trabeculectomy with mitomycin C by decreasing scarring.&#xD;
&#xD;
      The aim of the study is to evaluate the difference in failure rates and bleb morphology at&#xD;
      one year post-operatively in eyes having undergone sub-conjunctival injections of ranibizumab&#xD;
      in addition to primary trabeculectomy with mitomycin C compared to eyes having undergone&#xD;
      trabeculectomy with mitomycin C alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, unblinded clinical trial. Two groups of patients with glaucoma&#xD;
      undergoing primary trabeculectomy or phaco-trabeculectomy with MMC between March 2009 and&#xD;
      September 2012. The ranibizumab group (RAN) received 2 subconjunctival injections of 0.5 mg&#xD;
      of ranibizumab (intraoperatively and on day 14) and he control group did not receive&#xD;
      ranibizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure rates of the surgery as defined by intraocular pressure reductions</measure>
    <time_frame>one year</time_frame>
    <description>Complete success: post-operative IOP between 5-18 mm Hg and at least a 20% reduction in IOP from baseline without the use of glaucoma medications. Qualified success: similar definition with the use of glaucoma medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleb morphology using Moorfields bleb grading system</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabeculectomy with mitomycin C and standard post-operative care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Two ranibizumab subconjunctival injections (0.5 mg âˆ• 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.</description>
    <arm_group_label>ranibizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>standard post-operative care after trabeculectomy with mitomycin C</description>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  to have uncontrolled glaucoma&#xD;
&#xD;
          -  to have accepted to undergo a primary trabeculectomy with mitomycin C&#xD;
&#xD;
          -  to have one of the following types of glaucoma:&#xD;
&#xD;
               -  Normal tension Glaucoma&#xD;
&#xD;
               -  Chronic Open-Angle Glaucoma&#xD;
&#xD;
               -  Chronic Angle-Closure Glaucoma&#xD;
&#xD;
               -  Mixed mechanism glaucoma&#xD;
&#xD;
               -  Steroid-induced Glaucoma&#xD;
&#xD;
               -  Neovascular Glaucoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  to be less than 18 years old&#xD;
&#xD;
          -  to be unable to observe the study protocol&#xD;
&#xD;
          -  to present some risk factors for thromboembolic events and cerebrovascular accidents :&#xD;
             hypertension, dyslipidemia, coronary artery diseases&#xD;
&#xD;
          -  a history of thromboembolic events and cerebrovascular accidents&#xD;
&#xD;
          -  congenital glaucoma&#xD;
&#xD;
          -  uveitic glaucoma&#xD;
&#xD;
          -  to be pregnant&#xD;
&#xD;
          -  to be breastfeeding&#xD;
&#xD;
          -  surgical complications prior to injection of the study drug such as vitreous in the&#xD;
             anterior chamber or the presence of suprachoroidal hemorrhages&#xD;
&#xD;
          -  to have undergone a previous conjunctival surgery&#xD;
&#xD;
          -  to be hypersensitive to the drug, to one of the components of the drug or to one of&#xD;
             the components of the packaging&#xD;
&#xD;
          -  to present an active or suspected intraocular or periocular inflammation&#xD;
&#xD;
          -  to have a kidney failure&#xD;
&#xD;
          -  to have a liver failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisele Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Gisele Li</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Trabeculectomy</keyword>
  <keyword>Vascular Endothelial Growth Factor A</keyword>
  <keyword>Wound Healing</keyword>
  <keyword>Angiogenesis Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

